Plain-language care guide

Tirzepatide specialists: know what you are looking for

This is a guide to understanding tirzepatide care and finding a licensed prescriber. A prescriber is the doctor or other licensed clinician who checks your health and writes the prescription. It does not sell medicine, match people with clinics or arrange treatment.

Get the short answer Use the question cards

Pastel paper clouds surrounding a crisp checklist and magnifying glass — A calm place to sort out three things: the medicine’s name, the person prescribing it and the pharmacy.

Quick card

The short answer

A useful specialist makes the product, the reason for treatment, the follow-up plan and the full cost clear.

What it is

One ingredient, two approved brands

Tirzepatide copies two natural gut hormones at once. Both hormones signal fullness to the brain and help the body deal with the sugar that follows a meal.

As of September 2026, the FDA-approved brands were Mounjaro and Zepbound.

Under the labels current in September 2026, Mounjaro is approved for type 2 diabetes. It is also approved to lower the risk of heart attack and stroke in adults with diabetes who are at high risk. Zepbound is approved for long-term weight management in adults with obesity, or overweight with a weight-related health problem. It is also approved for obstructive sleep apnea in adults with obesity, a sleep problem in which breathing is interrupted again and again.

Plain words

“Tirzepatide” is the ingredient

Mounjaro and Zepbound contain the same active ingredient, but their approved uses are not the same. The name on the prescription matters because it can change the reason listed for treatment and the insurance path.

GIP and GLP-1: Short names for the two natural gut hormones that tirzepatide copies. Medicines that copy GLP-1 are often called GLP-1 drugs.
FDA-approved: The agency reviewed a specific product for its named use.

What it is not

No approved generic, and no current shortage listing

In September 2026, no generic version of tirzepatide had FDA approval.

As of September 2026, tirzepatide was not listed in the FDA’s national drug-shortage database.

While tirzepatide was on that shortage list, FDA held off acting against pharmacies that made their own copies of it. That hold ended on February 18, 2025 for ordinary pharmacies and on March 19, 2025 for larger batch-making facilities.

The compounding line

A pharmacy-made version is a different product

Compounding means a pharmacy mixes or makes a medicine to order, instead of handing over a ready-made product from a drug company.

As of September 2026, compounded tirzepatide was not FDA-approved, and FDA did not check a compounded drug’s safety, effect or quality before it was marketed.

As of September 2026, a pharmacy-made version could be legal. FDA said it might suit a patient whose medical need an approved medicine could not meet.

Ask for the exact product name, who made it and why a compounded version is being proposed.

Care card

Real care starts with an assessment

A product menu is not a medical visit. There needs to be room for the clinician to learn what matters about you and for you to ask questions back.

Confirm the person

Get the prescriber’s full name, profession and licence details. State rules differ, so use the official board record for the state where you will be during the visit.

Expect a real history

A careful prescriber asks about thyroid cancer in the family, pancreas or gallbladder trouble, serious stomach problems, diabetic eye disease, pregnancy plans, birth control pills, diabetes medicines and upcoming surgery.

Leave with a follow-up route

Guidance from the national group of state medical boards says a video, phone or online visit must be as careful as a visit in a room. If an assessment needs a test or physical exam, the prescriber needs to arrange it or refer you.

Evidence card

What a major weight trial found

Trials answer what happened to groups under study conditions. They do not predict one person’s result.

15–21% average body-weight loss

SURMOUNT-1, a large weight-loss study

In the SURMOUNT-1 trial, adults without diabetes lost an average of about 15% to 21% of body weight over 72 weeks. The amount depended on which strength of the medicine each group was given. People given a dummy shot lost about 3%.

Eli Lilly, the company that makes tirzepatide, paid for the trial. People in it also had regular visits and advice on eating and exercise. Keep both in mind when a clinic quotes these numbers.

Read the published study summary

The longer view

Stopping changed the result in another trial

In SURMOUNT-4, people switched to a dummy shot after 36 weeks on tirzepatide regained about 14% of body weight over the following 52 weeks, while the group that continued tirzepatide lost more.

That result is not an instruction to stay on the medicine. It does give you a question for the prescriber: what is the plan if I stop, and what is the plan if I carry on?

Safety card

Know the warnings before the sales pitch

Bring the hard parts into the first conversation. A short, specific answer is more useful than “it is safe.”

Boxed warning

Thyroid-tumor warning

Both tirzepatide labels carry the FDA’s strongest warning, about thyroid tumors found in rat studies; whether tirzepatide causes these tumors in people is not known.

The labels rule it out if you or a family member has had medullary thyroid cancer, a rare kind of thyroid cancer. They also rule it out for people with MEN 2, a rare inherited condition, and after a serious allergic reaction to tirzepatide. If you are unsure which kind of thyroid cancer runs in your family, ask the prescriber.

Common does not mean trivial

Across two Zepbound weight trials, roughly 25 to 29 of every 100 people on the medicine reported nausea, compared with 8 in every 100 given a dummy shot.

Other risks belong in the visit

The label warns about severe stomach problems, kidney injury after fluid loss, gallbladder disease, pancreas inflammation and serious allergic reactions.

Other medicines and procedures matter

The labels warn about low blood sugar when tirzepatide is combined with insulin or certain diabetes pills, worsening diabetic eye disease in people who already have it, and food entering the lungs during anesthesia.

Take the safety questions

Cost card

Ask for the whole cost, not the headline

The useful number covers the visit and the medicine plus lab work, supplies, shipping and follow-up. Online care often puts membership and medicine on separate bills.

Cash prices from the maker

$299–$699

As of September 26, 2026, Lilly sold Zepbound straight to people paying cash, without insurance. A month of vials, or of the KwikPen, a pen that holds four weekly doses, cost $299 to $699. Lower strengths cost less. Higher strengths cost $449 if each refill was bought within 45 days, and up to $699 if not.

List-price range

$499–$1,086.37

As of September 26, 2026, Lilly published a Zepbound list-price range of $499 to $1,086.37 per fill. A list price is the maker’s official published price, and few people actually pay it.

The maker offers described here ran only through December 31, 2026, so these figures need a fresh check after that date.

Insurance changes the route

As of September 26, 2026, maker savings cards could bring a fill to as little as $25 for some people with workplace or private insurance, but Medicare, Medicaid and military coverage were excluded from those cards.

Medicare has a narrow temporary path

As of September 26, 2026, some people with a Medicare drug plan could get Zepbound for weight loss for $50 a month or less. This came through a temporary Medicare program with its own rules on who qualifies. Only the KwikPen was included, not vials or single-dose pens. Ask the drug plan whether you qualify.

Source cards

Go past the sales page

These are the records behind the shortest useful checks.

Label

Current Zepbound prescribing information

Approved uses, boxed warning, common side effects and other label warnings.

Open DailyMed

Status

FDA compounding and shortage record

The dated federal record for the shortage ending and the compounding grace periods.

Open the FDA record

Put an option through the checks

Use one page of questions for the prescriber, product, pharmacy, safety plan and price.

Open the question cards